News Scan for Jun 03, 2021

News brief

ICU beds increased a net 10% during early COVID-19

US intensive care unit (ICU) beds increased a net 10% amid the COVID-19 pandemic, from April to July 2020, over 2019 baselines, according to a study today in Infection Control & Hospital Epidemiology.

The researchers used the National Healthcare Safety Network to look at 3,867 hospitals (67.5% of eligible hospitals) that had data from 2019 and 2020. Early in the pandemic, 30,279 beds were added to the 84,631 ICU beds available in 2019 (a 35.8% increase), while 21,507 were removed (25.4% of baseline). This made for a net 10.4% increase; however, beds were added or taken away unequally across different hospitals.

For instance, about 61% of large hospitals (221 ICU beds or more) and 16% of small hospitals (25 or fewer ICU beds) increased capacity from April to July 2020. General acute care hospitals (ACHs) were the most likely type of hospital to see increases, with 48% of sites recording upticks, but long-term acute care hospitals (LTACHs) saw the largest surge, with a 156% increase in capacity. Surgical and orthopedic hospitals, on the other hand, decreased ICU beds by 53%.

Overall, 39.1% of hospitals reported a positive net percentage change in ICU beds in 2020, compared with 35.1% that experienced a negative net change.

Geographic region trends generally followed COVID-19 case trends. The highest peak was a 59% increase in the Upper Northeast region on May 8, and the greatest drop was 32% in the Northern Plains on Apr 15. The researchers note that later, on Jul 11, the latter region increased ICU bed capacity 11%.

"As large ACHs and LTACHs increased their ICU capacity, smaller hospitals and those that provide primarily elective services may have experienced declines in patient visits, resulting in the same or fewer ICU beds maintained by these hospitals," the researchers write. "These results can be used to inform future emergency planning initiatives and resource allocation."
Jun 3 Infect Control Hosp Epidemiol study

 

Five blood clotting events occurred in COVID vaccinees in South Africa

Five blood clotting events occurred among almost 290,000 healthcare workers vaccinated with the AstraZeneca/Oxford COVID vaccine in South Africa, according to interim safety data published yesterday in a New England Journal of Medicine letter.

The AstraZeneca/Oxford vaccine, which had its emergency use paused by the South Africa Health Products Regulatory Authority earlier in the year, is currently undergoing a phase 3b trial in what will be a 500,000-person cohort of South African healthcare workers. The interim data include 288,368 vaccinated persons between Feb 17 and Apr 12.

About 2% of all participants reported adverse events, 81% of which were mild-to-moderate reactogenicity. Fifty events were of serious or of special interest, such as getting infected with the coronavirus within 28 days post-vaccination (12), allergic reactions (12, one of which was anaphylaxis), and neurological conditions (6), including a 40-year-old man who was later diagnosed as having Guillain-Barré syndrome and a 53-year-old woman with Bell's palsy.

Five arterial, venous thrombotic, or embolic events occurred in five participants with known risk factors (1.7 events per 100,000 people; less than 0.002% of the cohort). All instances occurred in women 38 to 65 years. The only fatal clotting instance occurred 23 days post-vaccination in a 63-year-old woman who was overweight and had high blood pressure, diabetes, and a history of venous thrombosis.

While other patient comorbidities included HIV, rheumatic heart disease, chronic pulmonary emboli, and diabetes, one woman who experienced signs of a transient ischemic attack 8 days post-vaccination only had the noteworthy condition of giving birth to twins 9 months prior.

"The rate of adverse events with vaccination is low, and thromboembolic events have occurred mainly in persons with risk factors for thromboembolism," the researchers conclude. They add, "To date, no case of vaccine-induced immune thrombotic thrombocytopenia has been documented."
Jun 2 N Engl J Med study

 

CDC warns of Salmonella outbreak linked to frozen, breaded chicken

Yesterday the Centers for Disease Control and Prevention (CDC) announced a multistate Salmonella Enteritidis outbreak linked to breaded chicken products. So far 17 people in 6 states have been sickened, with illness onset dates ranging from Feb 21 to May 7.

No deaths have been reported, but 8 people required hospitalization, the CDC said. Of 12 people interviewed, 10 said they reported preparing and eating frozen breaded stuffed chicken products before getting sick.

"People reported buying many different brands of raw frozen breaded stuffed chicken products from multiple stores. When asked about how the products were prepared at home, seven people reported undercooking, microwaving, or air frying the product," said the CDC.

Illinois has the most cases with 6, followed by Minnesota (4) and Indiana (3). Arizona and Michigan each have reported a single case, and New York has two cases.

The CDC said to avoid Salmonella, people should cook raw chicken in the oven to 165°F. The CDC does not recommend using a microwave or air fryer to cook raw chicken.

According to a statement from the US Department of Agriculture Food Safety and Inspection Service (FSIS), the products linked to the outbreak may be labeled "chicken cordon bleu", chicken with “broccoli and cheese”, or "chicken Kiev. " The products may seem ready to eat, the FSIS warned, but are not fully cooked. As part of the investigation, Minnesota officials found the outbreak strain in product samples from retail stores, but the production lots haven't been linked to any of the known cases.
Jun 2 CDC outbreak notice
Jun 2 FSIS
statement

Stewardship / Resistance Scan for Jun 03, 2021

News brief

Antibiotic guidelines for COVID patients linked to reduced prescribing

Guidelines for antibiotic initiation and discontinuation for community-acquired bacterial pneumonia (CABP) in COVID-19 patients at a Chicago hospital were associated with reduced antibiotic prescribing and days of therapy (DOT), researchers reported yesterday in BMC Infectious Diseases.

Researchers at University of Chicago Medicine evaluated the duration of antibiotic therapy from Mar 1 to Apr 25, 2020, in COVID-19 patients who received at least one antibiotic for CABP before and after the Mar 28 implementation of the guidelines, which were developed by the hospital's antimicrobial stewardship program in conjunction with infectious diseases providers. Indications to initiate empiric antibiotics included the presence of leukocytosis, fever, or chest imaging suggestive of a bacterial infections. The researchers also assessed the rate of patients receiving empiric antibiotics, hospital length-0f-stay, 30-day readmissions, and in-hospital mortality.

The retrospective study involved 506 patients, with 102 in the pre-intervention period and 404 in the post-intervention period. Prior to the guidelines, 74.5% of patients with COVID-19 received antibiotics, compared with 42% after implementation of the guidelines. The median DOT in the post-intervention group was 1.3 days shorter than the pre-intervention group, and the DOT of antibiotics directed at atypical bacteria was reduced by 2.8 days. In addition, more patients in the post-intervention group were initiated on empiric antibiotics based on criteria consistent with the guidelines (68% vs 87%). No differences in clinical outcomes were observed between the two groups.

"To our knowledge, this is the first report of an antimicrobial stewardship intervention to reduce the prescribing of empiric antibiotics for CABP in COVID-19 patients," the study authors wrote. "Reductions in antibiotic use have important implications and can potentially reduce antimicrobial resistance and antibiotic-related toxicities."

The authors add that further studies are needed to examine the potential clinical impact of stewardship interventions targeting antibiotic prescribing for CABP in COVID-19 patients.
Jun 2 BMC Infect Dis study

 

UK government to invest in antibiotic development, improved access

The British government today announced a £1 million ($1.4 million USD) investment to help the Global Antibiotic Research and Development Partnership's (GARDP's) efforts to develop and expand access to treatments for drug-resistant infections.

The money from the Global Antimicrobial Resistance Innovation Fund, part of the UK Department of Health and Social Care (DHSC), will support GARDP's pipeline of new antibiotics and contribute to the development of SECURE, a new antibiotics initiative from GARDP and the World Health Organization. SECURE's mission is to expand global access to new antibiotics that treat drug-resistant infections and to existing antibiotics that are not widely available or suffer from supply-chain disruptions or shortages.

"We are extremely pleased by the UK's increased contribution at a time when COVID-19 has demonstrated the critical importance of preventing and preparing for pandemics, including the pandemic of drug-resistant infections," GARDP Director of Research and Development Seamus O'Brien, PhD, said in a DHSC press release. "By investing an additional £1 million, the UK is again demonstrating leadership in efforts to accelerate the development and delivery of life-changing and life-saving treatments for every person who needs them."

The UK government to date has committed £13 million to GARDP.
Jun 3 DHSC press release

This week's top reads